Compare · INCY vs MEDP
INCY vs MEDP
Side-by-side comparison of Incyte Corp. (INCY) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $23.30B, about 1.5x MEDP ($15.36B).
- Over the past year, INCY is up 69.9% and MEDP is up 68.7% - INCY leads by 1.1 points.
- INCY has been more active in the news (21 items in the past 4 weeks vs 5 for MEDP).
- Both have 25 recent analyst ratings on file.
- Company
- Incyte Corp.
- Medpace Holdings Inc.
- Price
- $117.26+0.48%
- $538.04+0.04%
- Market cap
- $23.30B
- $15.36B
- 1M return
- +17.47%
- +16.49%
- 1Y return
- +69.87%
- +68.73%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 21
- 5
- Recent ratings
- 25
- 25
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest INCY
- Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
- President, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 22,919 shares, decreasing direct ownership by 10% to 217,929 units (SEC Form 4) (tax withholding)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 1,949 shares, decreasing direct ownership by 3% to 57,712 units (SEC Form 4) (tax liability)
- Principal Accounting Officer Tray Thomas covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 9% to 18,865 units (SEC Form 4) to cover withholding tax
- CMO & Head of Late-Stage Dev. Stein Steven H sold $3,192,193 worth of shares (28,237 units at $113.05) and covered exercise/tax liability with 24,918 shares, decreasing direct ownership by 70% to 22,995 units (SEC Form 4) (for tax liability)
- EVP, Head of U.S. Commercial Issa Mohamed Khairie covered exercise/tax liability with 1,099 shares, decreasing direct ownership by 2% to 65,033 units (SEC Form 4) to satisfy withholding tax
- Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
- Incyte to Report Second Quarter Financial Results
- Chief Executive Officer Meury William covered exercise/tax liability with 4,779 shares, decreasing direct ownership by 3% to 156,322 units (SEC Form 4) (withholding tax)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 350 shares, decreasing direct ownership by 0.58% to 59,661 units (SEC Form 4) to cover taxes
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.